Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One to Provide Decision Support for Guardant360 Cell-Free DNA Test

NEW YORK (GenomeWeb) – Diagnostics developer Guardant Health has inked a deal with molecular data interpretation firm N-of-One to provide decision support services for its Guardant360 test.

The diagnostic uses next-generation sequencing to analyze cell-free DNA, tumor fragments shed into the blood at low concentrations. The test can be used to gauge genetic alterations driving various tumor types and can be used by doctors to inform personalized medicine strategies for patients or guide them to clinical trials.

The companies did not disclose the financial terms of their deal.

Guardant announced the commercial launch of Guardant360 in February. In April, Guardant, in partnership with Khosla Ventures, Pejman Mar, and Sequoia Capital, raised $30 million in Series B financing to accelerate and expand commercialization efforts behind the test.

In a statement, Chris Cournoyer, CEO of N-of-One, suggested that the company hopes its data interpretation services will help Guardant scale its test volumes in a cost-effective fashion.